TERAPI FAVIPIRAVIR PADA SUBYEK COVID-19 DERAJAT SEDANG TANPA GANGGUAN LIVER DI RS PUSAT INFEKSI PROF DR SULIANTI SAROSO

Authors

  • Hastutik Cairn Brisbane Program Studi Magister Farmasi Klinis, Fakultas Farmasi Universitas Surabaya
  • Abdul Rahem Departemen Farmasi Praktis, Fakultas Farmasi Universitas Airlangga
  • Anita Purnamayanti Laboratorium Klinis Komunitas, Fakultas Farmasi Universitas Surabaya3
  • Rosamarlina Rosamarlina UPF Paru RS Pusat Infeksi Prof. dr. Sulianti Saroso
  • Memy Aviatin Instalasi Farmasi RS Pusat Infeksi Prof. dr. Sulianti Saroso
  • Adria Rusli UPF Paru RS Pusat Infeksi Prof. dr. Sulianti Saroso

DOI:

https://doi.org/10.36387/jiis.v7i2.880

Keywords:

Favipiravir, Moderate covid-19, Liver, Inpatient

Abstract

The outbreak of the corona virus which first contracted in December 2019 in Wuhan, China; Currently it has been designated by the World Health Organization (WHO) as a pandemic and is known as Corona Virus Infection Disease 2019 (Covid-19). This study aimed to describe the profile of favipiravir therapy in moderate COVID-19 inpatients without liver impairment at Prof. dr. Sulianti Saroso Infection Center Hospital. The design of this study was an observational study conducted retrospectively. All the patients in this research were received favipiravir loading dose of 1600 mg bid on the first day, and 600 mg bid starting on the day-2 of therapy.  The results of the research were 81 moderate Covid-19 inpatients without history or recent liver impairment who were hospitalized in the period October 2020 - July 2021 dominating by female gender (56%). Mode of hospital admission were self-referral to Prof. dr. Sulianti Saroso Infection Center Hospital (83%), primary care (Puskesmas) referral (12%), and other hospital referral (5%). There were no comorbidity in 74,1% of the subjects. Among 25,9% subjects with comorbidity, most of the patients suffered from hypertension (29%); hypertension, and cardiovascular disease (17%). diabetes (12%); diabetes and hypertension (12%); Asthma (12).  None of the subjects experienced increased in liver transaminases (ALT, AST), nor ALP and total bilirubin. Eighty-one patients were either cured (12%) with negative PCR test results or improved (88%) at the end of the therapy.

Published

2022-10-31

How to Cite

Brisbane, H. C., Rahem, A., Purnamayanti, A., Rosamarlina, R., Aviatin, M., & Rusli, A. (2022). TERAPI FAVIPIRAVIR PADA SUBYEK COVID-19 DERAJAT SEDANG TANPA GANGGUAN LIVER DI RS PUSAT INFEKSI PROF DR SULIANTI SAROSO. Jurnal Ilmiah Ibnu Sina, 7(2), 261–269. https://doi.org/10.36387/jiis.v7i2.880

Issue

Section

Article

Most read articles by the same author(s)